reported that VEGF expression in tumor cells may be mediated by soluble B7-H3 (25), suggesting that the combination of anti-VEGFR and anti-B7-H3 or the construction of bispecific CAR-T cells embedded with VEGFR and B7-H3 may constitute a sound approach. This evidence concerns the gene CD276 and neoplasm.